1669 related articles for article (PubMed ID: 27496136)
1. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
2. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
3. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
[TBL] [Abstract][Full Text] [Related]
6. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
[TBL] [Abstract][Full Text] [Related]
10. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Honma Y; Shimizu S; Takehara T; Harada M
J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
[TBL] [Abstract][Full Text] [Related]
12. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
13. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
16. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
18. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
19. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
[TBL] [Abstract][Full Text] [Related]
20. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]